In this paper, the authors developed ADLiB, a cfDNA-based liquid biopsy platform that distinguished malignant from benign lymphadenopathy with 95% sensitivity and 92% accuracy. This approach could improve #lymphoma diagnosis in resource-limited settings.. 📰https://bit.ly/4dDkXgr

#ND-LCH has few effective treatment options. In this paper, the authors found that #MAPK inhibitors improved clinical outcomes in 55% of children and MRI findings in 74%, with manageable side effects. Discover the findings: https://bit.ly/4vr1EwA

For previously untreated #FL patients ineligible for chemoimmunotherapy, the authors found that adding ibrutinib to rituximab improved progression-free survival and response rates versus rituximab alone. This paper explores the trade-off between efficacy and safety 👉https://hsphere.pub/fgs

In relapsed/refractory #AL amyloidosis, teclistamab produced rapid, deep hematologic responses and meaningful organ responses in a heavily pretreated cohort. Infection risk remains a key concern, with findings supporting concomitant immunoglobulin replacement therapy. 📰 https://hsphere.pub/70f

🚨Explore the June issue: new EHA recommendations for hemoglobinopathies, plus advances in PNH, CAR T-cell therapy, FL, liquid biopsy and lymphoma biology across hematology. https://hsphere.pub/gjk👉 https://hsphere.pub/gjk #openaccess

New EHA Guidelines for #CLL take a more holistic approach to care, from diagnosis and active surveillance through treatment decisions and Richter transformation. Read more:https://bit.ly/4veuXTm

Ever wonder why some cancer models don’t quite match real patients? Here's the truth. 🧬Knock-in mouse models show that natural mutation levels matter—and that biallelic TP53 loss is what truly drives leukemia #CancerResearch https://hsphere.pub/d3z

Phase IB/II trial of obinutuzumab, venetoclax and lenalidomide in high tumor burden follicular lymphoma: primary analysis of the LEVERAGE trial. Read more about this 👉https://bit.ly/4uRBYtj account=@chanyooncheah

This paper suggests that some patients with relapsed or refractory multiple myeloma can maintain durable remission after stopping bispecific antibody therapy. The authors also report gradual immune recovery and lower infection risk over time. Read more: https://bit.ly/3PQNcPD #MM

This paper highlights #MAPK inhibitors as a promising therapeutic approach for children with neurodegenerative Langerhans cell histiocytosis. The authors report clinical and MRI improvement in many patients, with manageable safety findings. 👉https://hsphere.pub/xga

This study reveals active crosstalk between lymphoma cells and M2-like TAMs, as well as TAM-mediated resistance mechanisms to CD19 #CAR T cells, which can be circumvented by targeting FR-beta. 👉https://bit.ly/4dOG3XR

🚨Explore the June issue: new EHA recommendations for hemoglobinopathies, plus advances in PNH, CAR T-cell therapy, FL, liquid biopsy and lymphoma biology across hematology. https://hsphere.pub/gjk👉 https://hsphere.pub/gjk #openaccess

This paper shows that CDK6 inhibition enhances interferon responsiveness in #MPN cells, identifying a potential therapeutic window for combining palbociclib with pegIFNα, supporting further study of this approach in MPN therapy. Read here 📰https://bit.ly/4uO44p2

Var‑cel (ARI-0001) CAR‑T shows strong positive outcomes in R/R Mantle Cell Lymphoma #MCL: 89% ORR, 78% CR, minimal severe CRS/ICANS, and long survival (PFS 15.4/OS 35.2 mo) in a Spanish multicenter cohort. Read the details here: https://bit.ly/4nGObOR

This paper shows that JAK2-V617F mutant #HSCs can outcompete normal HSCs and initiate #MPN without irradiation or elevated cytokines.  Delve deeper 🔎https://bit.ly/4tzIiVB

This recently published paper shows that persistent BCR::ABL1 positivity in Ph+ ALL can mark a preleukemic reservoir that expands after TKI withdrawal.  Read more in the June issue 🔎 https://bit.ly/4urL0Nm

Offering consensus guidance on when and how to screen for thalassemia and sickle cell disease carriers, including clear communication that respects cultural context and supports informed reproductive choices. See how the authors frame these recommendations here 👉https://bit.ly/4fO3Xp0

p53 in normal blood formation + MPNs. Dr Charles de Bock talks with Dr Isabelle Plo & Dr Barbara Monte-Mór on TP53 mutations, leukemic transformation, and emerging p53‑targeted therapies. Listen: https://bit.ly/4tq6QQ2 Review: https://bit.ly/4sZbo01

Authors of this paper offer reassuring real-world evidence for clinicians treating lymphoma patients with prior #HBV exposure, showing that, with antiviral prophylaxis, occult HBV infection should not preclude anti-CD19 #CAR-T therapy. https://bit.ly/4tTOoQ2

This paper shows poor survival after relapse following second-line #CAR T-cell therapy in large B-cell lymphoma #LBCL. The authors highlight the need for new strategies and dedicated trials. Read more 👉https://bit.ly/42SwX7j

New Episode! Host Dr Charles de Bock delves into ground-breaking preclinical research exploring the potential of tasquinimod to restore blood cell production and modify the bone marrow microenvironment in #MDS with Dr Manja Wobus and Dr Katja Sockel 🎧 https://hsphere.pub/wom

This paper reviews emerging in vivo #CAR therapies, outlining delivery platforms, clinical progress, and key challenges. The authors highlight how these approaches could help overcome manufacturing and access barriers in cell therapy. Read in depth 🔎https://bit.ly/4d1mfjP

At #EHA2026, we were honored to issue our final #HemaSphereAwards to our top 2025 peer-reviewer, Austin Kulasekararaj. We are grateful for Austin's outstanding peer-review contributions and for supporting the hematology publication landscape. 🙌

At #EHA2026, the #HemaSphereAwards recognize authors of influential heme publications. Congrats to Maximilian Merz, Nico Gagelmann, & coauthors for their highly cited (WoS) paper on idec-cel or cilta-cel for #RRMM 👉https://onlinelibrary.wiley.com/doi/10.1002/hem3.70070 @nicogagelmann.bsky.social

This paper identifies IGH::BCL3-positive #CLL as a distinct biological subtype with shared genetic and epigenetic features. Authors also suggest venetoclax may help overcome poor outcomes seen with chemoimmunotherapy.  Read about it here 👉https://bit.ly/4unom8F

At #EHA2026, the #HemaSphereAwards recognize authors of influential heme publications. Congratulations to Achille Iolascon, Ali Taher, & coauthors for their guidelines publication on diagnosis, tx, & prevention of iron deficiency + anemia👉https://onlinelibrary.wiley.com/doi/10.1002/hem3.108

At #EHA2026, the #HemaSphereAwards recognize authors of influential hematology publications. Congratulations to Ana Luísa Pereira, Serena Galli, and César Nombela-Arrieta for their study on bone marrow niches for hematopoietic stem cells👉https://onlinelibrary.wiley.com/doi/10.1002/hem3.133

At #EHA2026, the #HemaSphereAwards recognize authors of influential hematology publications. Congrats to Evgenii Shumilov, Georg Lenz, & coauthors for their study on CAR-T efficacy & toxicity in pts with DLBCL aged 70+ compared to younger pts👉https://onlinelibrary.wiley.com/doi/10.1002/hem3.54

Are you at #EHA2026 and need a break? Find our nook by the amazing poster area. Have a seat, charge your phone, chat with colleagues.

This Perspective outlines major gaps in #AYA hematology care across Europe. The authors call for shared standards, better transition support, and stronger research to improve outcomes.  Read more from the authors here:  https://bit.ly/42LFKYX @EHA_Hematology